Magrolimab (Not yet branded)

Immunotherapy

Experimental

med_spain_not_available IV 2 Clinical Trials

CD47

Description

Magrolimab (Hu5F9-G4) is a monoclonal antibody immunotherapy that targets the CD47 protein on cancer cells. In colorectal cancer treatment, it is being combined with established regimens including FOLFIRI/bevacizumab for previously treated metastatic disease and with cetuximab for advanced cases. This anti-CD47 antibody works to enhance immune system recognition and destruction of cancer cells by blocking the "don't eat me" signal that tumors use to evade immune surveillance.

Mechanism of Action

Magrolimab binds to CD47, a transmembrane protein overexpressed on many cancer cells that serves as a "don't eat me" signal to macrophages. By blocking CD47, magrolimab enables macrophages to recognize and phagocytose cancer cells, while also promoting adaptive immune responses through enhanced antigen presentation. This mechanism complements other therapies by removing a key immune evasion strategy used by colorectal tumors.

Molecular Targets

CD47

Side Effects

Anemia Thrombocytopenia Neutropenia Fatigue Headache Infusion-related reactions Nausea Diarrhea

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT05330429 med_phase_prefix2

Terminated

Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)

United States, Australia, Belgium, Canada, France, Germany, Hong Kong, Italy, Pu

NCT02953782 med_phase_prefix1

Archived

Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer

United States

Quick Info

Brand Name	Not yet branded
Category	Immunotherapy
Status	Experimental
Estado EMA	Experimental
Acceso España	med_spain_not_available
Administration	IV
Clinical Trials	2

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.